MERRILL CORP /NEW/ - FA 3
3 · MERRILL CORP /NEW/ - FA · Filed May 11, 2015
Insider Transaction Report
Form 3
Skyline Venture Partners V LP
10% Owner
Holdings
- (indirect: see footnote)
Series C Convertible Preferred Stock
→ Common Stock (382,323 underlying) - (indirect: see footnote)
Series B Convertible Preferred Stock
→ Common Stock (1,552,795 underlying) - (indirect: see footnote)
Series D Convertible Preferred Stock
→ Common Stock (852,423 underlying)
Footnotes (2)
- [F1]All series of Convertible Preferred Stock will automatically convert into Collegium Pharmaceutical, Inc. common stock on a 1-for-6.9 basis immediately prior to the closing of the initial public offering and have no expiration date.
- [F2]The shares are held by Skyline Venture Partners V, L.P. The general partner of Skyline Venture Partners V, L.P. is Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management, LLC and disclaim beneficial ownership of all the shares held by Skyline Venture Partners V, L.P. except to the extent of their proportionate pecuniary interest therein. Dr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports.